Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001140361-24-016132
Filing Date
2024-03-28
Accepted
2024-03-28 16:12:43
Documents
85
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K ef20015360_10k.htm   iXBRL 10-K 2914335
2 EXHIBIT 23.1 ef20015360_ex23-1.htm EX-23.1 2543
3 EXHIBIT 31.1 ef20015360_ex31-1.htm EX-31.1 13001
4 EXHIBIT 31.2 ef20015360_ex31-2.htm EX-31.2 13059
5 EXHIBIT 32.1 ef20015360_ex32-1.htm EX-32.1 5327
6 EXHIBIT 32.2 ef20015360_ex32-2.htm EX-32.2 5639
7 EXHIBIT 97.1 ef20015360_ex97-1.htm EX-97.1 37859
  Complete submission text file 0001140361-24-016132.txt   10490726

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA knte-20231231.xsd EX-101.SCH 53264
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE knte-20231231_cal.xml EX-101.CAL 63015
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE knte-20231231_def.xml EX-101.DEF 297783
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE knte-20231231_lab.xml EX-101.LAB 734382
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE knte-20231231_pre.xml EX-101.PRE 504953
89 EXTRACTED XBRL INSTANCE DOCUMENT ef20015360_10k_htm.xml XML 1663933
Mailing Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130
Business Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130 8582994699
Kinnate Biopharma Inc. (Filer) CIK: 0001797768 (see all company filings)

EIN.: 824566526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39743 | Film No.: 24799045
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)